The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib
Version 2 : Received: 23 January 2021 / Approved: 25 January 2021 / Online: 25 January 2021 (13:17:31 CET)
How to cite: Robak, P.; Jarych, D.; Mikulski, D.; Drozd, I.; Węgłowska, E.; Kotkowska, A.; Misiewicz, M.; Smolewski, P.; Stawiski, K.; Fendler, W.; Szemraj, J.; Robak, T. The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib. Preprints 2020, 2020120287. https://doi.org/10.20944/preprints202012.0287.v1 Robak, P.; Jarych, D.; Mikulski, D.; Drozd, I.; Węgłowska, E.; Kotkowska, A.; Misiewicz, M.; Smolewski, P.; Stawiski, K.; Fendler, W.; Szemraj, J.; Robak, T. The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib. Preprints 2020, 2020120287. https://doi.org/10.20944/preprints202012.0287.v1
Abstract
Keywords
Subject
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)